Literature DB >> 26392504

Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Andrew J Neville1, Sydney J Zach1, Xiaofang Wang2, Joshua J Larson1, Abigail K Judge1, Lisa A Davis3, Jonathan L Vennerstrom2, Paul H Davis4.   

Abstract

Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26392504      PMCID: PMC4649158          DOI: 10.1128/AAC.02009-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  105 in total

1.  Quinupristin-dalfopristin is active against Toxoplasma gondii.

Authors:  A A Khan; T R Slifer; F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii.

Authors:  Christopher P Hencken; Lorraine Jones-Brando; Claudia Bordón; Remo Stohler; Bryan T Mott; Robert Yolken; Gary H Posner; Lauren E Woodard
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

Review 3.  Veterinary vaccines against Toxoplasma gondii.

Authors:  Elisabeth A Innes; Paul M Bartley; Stephen Maley; Frank Katzer; David Buxton
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

4.  Toxoplasma encephalitis: influence of the vehicle on the efficacy of different doses of 2',3'-dideoxyinosine in mice.

Authors:  A Gherardi; M E Sarciron; F Peyron
Journal:  Parasite       Date:  2000-03       Impact factor: 3.000

Review 5.  Anti-Toxoplasma activity of natural products: a review.

Authors:  Juan C Sepulveda-Arias; Luz A Veloza; Luz E Mantilla-Muriel
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2014

6.  Decrease of psychomotor performance in subjects with latent 'asymptomatic' toxoplasmosis.

Authors:  J Havlícek; Z G Gasová; A P Smith; K Zvára; J Flegr
Journal:  Parasitology       Date:  2001-05       Impact factor: 3.234

7.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

8.  Activity of diclazuril against Toxoplasma gondii in cultured cells and mice.

Authors:  D S Lindsay; B L Blagburn
Journal:  Am J Vet Res       Date:  1994-04       Impact factor: 1.156

9.  Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice.

Authors:  Amanda J Payne; Lori M Neal; Laura J Knoll
Journal:  Parasitol Res       Date:  2013-08-16       Impact factor: 2.289

Review 10.  Recent advances in Toxoplasma gondii immunotherapeutics.

Authors:  Sherene Swee-Yin Lim; Rofina Yasmin Othman
Journal:  Korean J Parasitol       Date:  2014-12-23       Impact factor: 1.341

View more
  36 in total

1.  Novel Toxoplasma gondii inhibitor chemotypes.

Authors:  A G Sanford; T T Schulze; L P Potluri; R M Hemsley; J J Larson; A K Judge; S J Zach; X Wang; S A Charman; J L Vennerstrom; P H Davis
Journal:  Parasitol Int       Date:  2018-01-04       Impact factor: 2.230

Review 2.  Toxoplasma gondii and schizophrenia: a review of published RCTs.

Authors:  Sam D Chorlton
Journal:  Parasitol Res       Date:  2017-05-15       Impact factor: 2.289

3.  Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy.

Authors:  Jili Zhang; Hongfei Si; Kun Lv; Yanhua Qiu; Jichao Sun; Yubin Bai; Bing Li; Xuzheng Zhou; Jiyu Zhang
Journal:  Front Cell Dev Biol       Date:  2021-06-11

4.  Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Luis-Miguel Ortega-Mora; Javier Moreno-Gonzalo; Ignacio Ferre; Matthew A Hulverson; Ryan Choi; Molly C McCloskey; Lynn K Barrett; Dustin J Maly; Kayode K Ojo; Wes Van Voorhis; Andrew Hemphill
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

5.  Synergistic Activity between Statins and Bisphosphonates against Acute Experimental Toxoplasmosis.

Authors:  Zhu-Hong Li; Catherine Li; Sergio H Szajnman; Juan B Rodriguez; Silvia N J Moreno
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 6.  HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment.

Authors:  Lauren N Bowen; Bryan Smith; Daniel Reich; Martha Quezado; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2016-10-27       Impact factor: 42.937

Review 7.  Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.

Authors:  Madalyn M McFarland; Sydney J Zach; Xiaofang Wang; Lakshmi-Prasad Potluri; Andrew J Neville; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Interaction of apigenin-7-O-glucoside with pyrimethamine against Toxoplasma gondii growth.

Authors:  Daniel A Abugri; William H Witola
Journal:  J Parasit Dis       Date:  2019-12-02

9.  Evaluation of Current and Emerging Antimalarial Medicines for Inhibition of Toxoplasma gondii Growth in Vitro.

Authors:  Joshua B Radke; Jeremy N Burrows; Daniel E Goldberg; L David Sibley
Journal:  ACS Infect Dis       Date:  2018-07-25       Impact factor: 5.084

Review 10.  One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.

Authors:  Wesley C Van Voorhis; Matthew A Hulverson; Ryan Choi; Wenlin Huang; Samuel L M Arnold; Deborah A Schaefer; Dana P Betzer; Rama S R Vidadala; Sangun Lee; Grant R Whitman; Lynn K Barrett; Dustin J Maly; Michael W Riggs; Erkang Fan; Thomas J Kennedy; Saul Tzipori; J Stone Doggett; Pablo Winzer; Nicoleta Anghel; Dennis Imhof; Joachim Müller; Andrew Hemphill; Ignacio Ferre; Roberto Sanchez-Sanchez; Luis Miguel Ortega-Mora; Kayode K Ojo
Journal:  Vet Parasitol       Date:  2020-12-15       Impact factor: 2.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.